Human Recombinant FKBP14 protein, His Tag (V2LY-0526-LY4149)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host
HEK293 Cells
Protein Species
Human
Tag
His Tag
Protein Construction
This product is Human Recombinant FKBP14 protein, His Tag consist of Amino Acid: 1-207 and predicts a molecular mass of 22.9 kDa.
Molecule Mass
22.9 kDa
Sequence
Amino Acid: 1-207
Species
Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity
>95% as determined by SDS-PAGE
Endotoxin
Please contact us for more information.
Format
Lyophilized
Reconstitution
Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.
Buffer
Lyophilized from sterile PBS
Preservative
None
Storage
Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
More Infomation

Target

Full Name
FK506 Binding Protein 14
Function
PPIase which accelerates the folding of proteins during protein synthesis. Has a preference for substrates containing 4-hydroxylproline modifications, including type III collagen. May also target type VI and type X collagens.
Cellular Location
Endoplasmic reticulum lumen
Involvement in disease
Ehlers-Danlos syndrome, kyphoscoliotic type, 2 (EDSKSCL2):
A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSKSCL2 is an autosomal recessive form characterized by severe generalized hypotonia at birth, myopathy, early-onset progressive kyphoscoliosis, joint hypermobility without contractures, hyperelastic skin with follicular hyperkeratosis, easy bruising, and occasional abnormal scarring, sensorineural hearing impairment, and normal pyridinoline excretion in urine.

Semyachkina, A. N., Nikolaeva, E. A., Galeeva, N. M., Polyakov, A. V., Kurnikova, M. A., Belova, V. А., ... & Dzhivanshiryan, G. V. (2021). Ehlers-Danlos syndrome kyphoscoliotic type 2 caused by mutations in the FKBP14 gene: An analysis of five cases. F1000Research, 10(502), 502.

Colman, M., Vroman, R., Dhooge, T., Malfait, Z., Symoens, S., Burnyté, B., ... & Syx, D. (2022). Kyphoscoliotic Ehlers‐Danlos syndrome caused by pathogenic variants in FKBP14: Further insights into the phenotypic spectrum and pathogenic mechanisms. Human Mutation, 43(12), 1994-2009.

Bai, Y., Li, L., & Zhang, Z. (2022). Linc00883 affects colorectal cancer through miR-577/FKBP14 axis: a novel mechanism for regulating colorectal cancer cell proliferation, invasion, and migration. Cell Cycle, 21(22), 2403-2416.

Yang, L., Zhang, R., Yang, J., Bi, T., & Zhou, S. (2019). FKBP14 promotes the proliferation and migration of colon carcinoma cells through targeting IL-6/STAT3 signaling pathway. OncoTargets and therapy, 12, 9069.

Giunta, C., Rohrbach, M., Fauth, C., Baumann, M., Adam, M. P., Ardinger, H. H., ... & Amemiva, A. (2019). FKBP14 Kyphoscoliotic Ehlers-Danlos syndrome.

Lim, P. J., Lindert, U., Opitz, L., Hausser, I., Rohrbach, M., & Giunta, C. (2019). Transcriptome profiling of primary skin fibroblasts reveal distinct molecular features between PLOD1-and FKBP14-kyphoscoliotic Ehlers–Danlos syndrome. Genes, 10(7), 517.

Ghoorun, R. A., Wu, X. H., Chen, H. L., Ren, D. L., & Wu, X. B. (2019). Prognostic significance of fkbp14 in gastric cancer. OncoTargets and therapy, 12, 11567.

Castori, M., Fiorillo, C., Agolini, E., Sacco, M., Minetti, C., Novelli, A., ... & Bertini, E. (2019). Primary muscle involvement in a 15‐year‐old girl with the recurrent homozygous c. 362dupC variant in FKBP14. American Journal of Medical Genetics Part A, 179(2), 317-321.

Giunta, C., Baumann, M., Fauth, C., Lindert, U., Abdalla, E. M., Brady, A. F., ... & Rohrbach, M. (2018). A cohort of 17 patients with kyphoscoliotic Ehlers–Danlos syndrome caused by biallelic mutations in FKBP14: expansion of the clinical and mutational spectrum and description of the natural history. Genetics in Medicine, 20(1), 42-54.

Wang, K., Qi, X. J., Liu, H. Z., & Su, H. (2018). MiR-361 inhibits osteosarcoma cell lines invasion and proliferation by targeting FKBP14. Eur Rev Med Pharmacol Sci, 22(1), 79-86.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human Recombinant FKBP14 protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.